Home/Filings/4/0001213900-22-080968
4//SEC Filing

HSU ERIC C 4

Accession 0001213900-22-080968

CIK 0001728328other

Filed

Dec 18, 7:00 PM ET

Accepted

Dec 19, 4:49 PM ET

Size

5.8 KB

Accession

0001213900-22-080968

Insider Transaction Report

Form 4
Period: 2022-12-16
HSU ERIC C
Sr VP, Pre-Clinical Res/Dev
Transactions
  • Award

    Employee Stock Option (Right to Buy)

    2022-12-16+4,2008,878 total
    Exercise: $1.78Exp: 2027-12-15Common shares (4,200 underlying)
Footnotes (2)
  • [F1]The options were granted on 12/16/2022 and will vest as follows: 25% of stock options will vest 6 months after the date of Grant; 25% of stock options will vest 12 months after the date of the Grant; 25% stock options will vest 18 months after the date of the Grant; and 25% stock options will vest 24 months after the date of the Grant.
  • [F2]On September 7, 2022, the common stock of InMed was reverse split on a 1-for-25 basis. This number reflects that reverse stock split.

Documents

1 file

Issuer

InMed Pharmaceuticals Inc.

CIK 0001728328

Entity typeother

Related Parties

1
  • filerCIK 0001817867

Filing Metadata

Form type
4
Filed
Dec 18, 7:00 PM ET
Accepted
Dec 19, 4:49 PM ET
Size
5.8 KB